{"product_id":"the-2021-22-guide-to-medications-for-the-treatment-of-diabetes-mellitus-9781580407908","title":"The 2021-22 Guide to Medications for the Treatment of Diabetes Mellitus","description":"\u003cdiv class=\"book-description\"\u003e\n\u003cp\u003eNewly updated to reflect the latest research and medical guidance, \u003cem\u003eThe 2021-22 Guide to Medications for the Treatment of Diabetes Mellitus\u003c\/em\u003e offers a bridge between drug handbooks and pharmacology texts.\u003c\/p\u003e\n\n\u003cp\u003eFocusing entirely on diabetes drugs, this reference is divided into two sections:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eDrugs used to manage hyperglycemia\u003c\/li\u003e\n  \u003cli\u003eManagement of diabetic comorbidities\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe first section includes:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003ePharmacologic Therapy for Type 1 Diabetes\u003c\/li\u003e\n  \u003cli\u003eManagement of Hyperglycemia in Type 1 DM– info from practical use of insulin, pathophysiology, treatment strategy\u003c\/li\u003e\n  \u003cli\u003eInsulins: RAIAs, short-acting insulins, intermediate-acting insulins, LAIAs, concentrated insulins, insulin pumps and patches, inhaled insulins, mixed and mixing insulin, use in Type 1, use in Type 2\u003c\/li\u003e\n  \u003cli\u003ePharmacologic Therapy for Type 2 Diabetes\u003c\/li\u003e\n  \u003cli\u003eManagement of Hyperglycemia in Type 2– brief overview, pathophysiology, treatment strategy, overview of medications\u003c\/li\u003e\n  \u003cli\u003eBiguanides\u003c\/li\u003e\n  \u003cli\u003eTZDs\u003c\/li\u003e\n  \u003cli\u003eSUs\u003c\/li\u003e\n  \u003cli\u003eGlinides\u003c\/li\u003e\n  \u003cli\u003eSGLT-2 Inhibitors\u003c\/li\u003e\n  \u003cli\u003eAGIs\u003c\/li\u003e\n  \u003cli\u003eDPP-IV inhibitors\u003c\/li\u003e\n  \u003cli\u003eGLP Ras\u003c\/li\u003e\n  \u003cli\u003eAmylin mimetics\u003c\/li\u003e\n  \u003cli\u003eBARs\u003c\/li\u003e\n  \u003cli\u003eDA-2 agonists\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eEach chapter in Section 1 includes:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003eDrug class overview and role in diabetes treatment\u003c\/li\u003e\n  \u003cli\u003ePharmacology: \n    \u003cul\u003e\n      \u003cli\u003eMechanism of action\u003c\/li\u003e\n      \u003cli\u003ePharmacokinetics\u003c\/li\u003e\n    \u003c\/ul\u003e\n  \u003c\/li\u003e\n  \u003cli\u003eTreatment Advantages\/Disadvantages: \n    \u003cul\u003e\n      \u003cli\u003eGeneral for the class\u003c\/li\u003e\n      \u003cli\u003eWhen applicable, a discussion of evidence that supports the benefits of using a particular drug in a class over another in the same class (e.g., Avandia vs Actos)\u003c\/li\u003e\n    \u003c\/ul\u003e\n  \u003c\/li\u003e\n  \u003cli\u003eTherapeutic Considerations:\n    \u003cul\u003e\n      \u003cli\u003eSignificant Warnings\/Precautions\u003c\/li\u003e\n      \u003cli\u003eSpecial Populations\u003c\/li\u003e\n      \u003cli\u003ePharmacogenomics\u003c\/li\u003e\n      \u003cli\u003eAdverse effects and monitoring\u003c\/li\u003e\n      \u003cli\u003eDrug Interactions\u003c\/li\u003e\n      \u003cli\u003eDosage and administration\u003c\/li\u003e\n    \u003c\/ul\u003e\n  \u003c\/li\u003e\n  \u003cli\u003eTable with Doses and Dose Adjustments\u003c\/li\u003e\n  \u003cli\u003eList of important combination products\u003c\/li\u003e\n  \u003cli\u003eReferences\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThe second section includes:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eCardiovascular Disease and Risk Management\u003c\/li\u003e\n  \u003cli\u003eMicrovascular Complications and Foot Care\u003c\/li\u003e\n  \u003cli\u003eMedications for the Management of Hypertension\u003c\/li\u003e\n  \u003cli\u003eMedications for the Management of Hyperlipidemia\u003c\/li\u003e\n  \u003cli\u003eAntiplatelet Therapy\u003c\/li\u003e\n  \u003cli\u003eMedications for Smoking Cessation\u003c\/li\u003e\n  \u003cli\u003eMedications for the Management of Neuropathy (peripheral and autonomic)\u003c\/li\u003e\n  \u003cli\u003eMedications for the Management of Nephropathy\u003c\/li\u003e\n  \u003cli\u003eMedications for the Management of Retinopathy\u003c\/li\u003e\n  \u003cli\u003eMedications for the Management of Depression\u003c\/li\u003e\n  \u003cli\u003eMedications for the Management of Hypoglycemia\u003c\/li\u003e\n  \u003cli\u003eMedications for the Management of Obesity\u003c\/li\u003e\n  \u003cli\u003eImmunizations in Patients with Diabetes\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eEach chapter in Section 2 includes:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003eAn overview of the condition or problem\u003c\/li\u003e\n  \u003cli\u003eGoals of treatment\u003c\/li\u003e\n  \u003cli\u003eOverview of the medications and rationale for the medications used for the problem\u003c\/li\u003e\n  \u003cli\u003eOverview of each class of medication\u003c\/li\u003e\n  \u003cli\u003eOverview of combination therapy: \n    \u003cul\u003e\n      \u003cli\u003eFirst combination\u003c\/li\u003e\n      \u003cli\u003eSecond combination\u003c\/li\u003e\n    \u003c\/ul\u003e\n  \u003c\/li\u003e\n  \u003cli\u003eDoses and Dose Adjustments for the more salient medications\u003c\/li\u003e\n  \u003cli\u003eList of important combination products\u003c\/li\u003e\n  \u003cli\u003eReferences\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/div\u003e","brand":"Hachette Aotearoa New Zealand","offers":[{"title":"Default Title","offer_id":47487563890924,"sku":"9781580407908","price":150.0,"currency_code":"NZD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0705\/7784\/8556\/files\/671fe493d8ae2fa6cf83c8040bc99939.jpg?v=1775773994","url":"https:\/\/bookhero.co.nz\/products\/the-2021-22-guide-to-medications-for-the-treatment-of-diabetes-mellitus-9781580407908","provider":"Book Hero","version":"1.0","type":"link"}